CA3070494A1 - Use of 99mtc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions - Google Patents

Use of 99mtc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions Download PDF

Info

Publication number
CA3070494A1
CA3070494A1 CA3070494A CA3070494A CA3070494A1 CA 3070494 A1 CA3070494 A1 CA 3070494A1 CA 3070494 A CA3070494 A CA 3070494A CA 3070494 A CA3070494 A CA 3070494A CA 3070494 A1 CA3070494 A1 CA 3070494A1
Authority
CA
Canada
Prior art keywords
composition
tumor
imaging
subject
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3070494A
Other languages
English (en)
French (fr)
Inventor
Frederick O COPE
Bonnie Chandler Abbruzzese
David Allen RALPH
Allison KISSLING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Navidea Biopharmaceuticals Inc
Original Assignee
Navidea Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navidea Biopharmaceuticals Inc filed Critical Navidea Biopharmaceuticals Inc
Publication of CA3070494A1 publication Critical patent/CA3070494A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
CA3070494A 2017-07-21 2018-07-20 Use of 99mtc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions Pending CA3070494A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762535752P 2017-07-21 2017-07-21
US62/535,752 2017-07-21
PCT/US2018/043176 WO2019018815A1 (en) 2017-07-21 2018-07-20 USE OF 99MTC-TILMANOCEPT AND ASSOCIATED MOLECULAR CONSTRUCTS FOR THE IDENTIFICATION AND DIAGNOSIS OF MALIGNANT TUMORS, AND FOR THE MONITORING OF ANTI-TUMOR THERAPEUTIC INTERVENTIONS

Publications (1)

Publication Number Publication Date
CA3070494A1 true CA3070494A1 (en) 2019-01-24

Family

ID=65014640

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3070494A Pending CA3070494A1 (en) 2017-07-21 2018-07-20 Use of 99mtc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions

Country Status (7)

Country Link
US (1) US20190022259A1 (https=)
EP (1) EP3655107A4 (https=)
JP (1) JP2020528059A (https=)
CN (1) CN111447955A (https=)
CA (1) CA3070494A1 (https=)
IL (1) IL272123A (https=)
WO (1) WO2019018815A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3127487A1 (en) * 2019-01-25 2020-07-30 Navidea Biopharmaceuticals, Inc. Compositions and methods for assessing macrophage mediated pathology
US20210052639A1 (en) * 2019-08-19 2021-02-25 Navidea Biopharmaceuticals, Inc. Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells
US20210145989A1 (en) * 2019-09-30 2021-05-20 Navidea Biopharmaceuticals, Inc. Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands
EP4076540A4 (en) * 2020-07-08 2024-02-21 Navidea Biopharmaceuticals, Inc. Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof
CA3192041A1 (en) * 2020-08-21 2022-02-24 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
EP4472643A1 (en) 2022-02-04 2024-12-11 Navidea Biopharmaceuticals, Inc. Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
US20230302041A1 (en) * 2022-03-25 2023-09-28 Navidea Biopharmaceuticals, Inc. Competitive Self-Blocking with Unlabeled Manocept Imaging Agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671256A (en) * 1984-05-25 1987-06-09 Lemelson Jerome H Medical scanning, monitoring and treatment system and method
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
JP2005226021A (ja) * 2004-02-16 2005-08-25 Nihon Medi Physics Co Ltd マンノース受容体親和性化合物
CN114377143A (zh) * 2013-07-22 2022-04-22 康德乐健康414有限责任公司 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒
US20170202969A1 (en) * 2014-07-17 2017-07-20 Larry Schlesinger Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
CA2955438C (en) * 2014-07-17 2024-07-02 Ohio State Innovation Foundation DEXTRANE CONJUGATES TO TARGET MACROPHAGES AND OTHER CELLS EXPRESSING THE D-MANBOSE BINDING TYPE C LECTIN RECEPTOR
WO2016011419A1 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
US10806803B2 (en) * 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
WO2016118188A1 (en) * 2015-01-21 2016-07-28 Navidea Biopharmaceuticals, Inc. Compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells
WO2018067751A1 (en) * 2016-10-04 2018-04-12 Navidea Biopharmaceuticals, Inc. Compositions and methods for diagnosing and treating macrophage-related disorders using carbohydrate-based macromolecular carrier
MX2019004029A (es) * 2016-10-07 2019-09-27 Navidea Biopharmaceuticals Inc Compuestos y metodos para diagnosis y tratamiento de infecciones virales.
EP3522899A4 (en) * 2016-10-07 2020-05-06 Navidea Biopharmaceuticals, Inc. Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same

Also Published As

Publication number Publication date
US20190022259A1 (en) 2019-01-24
WO2019018815A1 (en) 2019-01-24
EP3655107A4 (en) 2021-04-28
IL272123A (en) 2020-03-31
JP2020528059A (ja) 2020-09-17
EP3655107A1 (en) 2020-05-27
CN111447955A (zh) 2020-07-24

Similar Documents

Publication Publication Date Title
CA3070494A1 (en) Use of 99mtc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions
US11020493B2 (en) Double-labeled probe for molecular imaging and use thereof
US10500292B2 (en) PSMA-binding agents and uses thereof
JP6824971B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）の１８ｆ−タグ付加インヒビターおよび前立腺癌についての画像化剤としてのその使用
US20220062448A1 (en) Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
CA2955438C (en) DEXTRANE CONJUGATES TO TARGET MACROPHAGES AND OTHER CELLS EXPRESSING THE D-MANBOSE BINDING TYPE C LECTIN RECEPTOR
CA2955441C (en) Dextran conjugates for targeting macrophages and other cd296-expressing cells
JP2008531755A (ja) 二重画像化および放射線化学療法のためのコンジュゲート：組成物、製造および適応
JP2018531243A6 (ja) 前立腺特異的膜抗原（ｐｓｍａ）の１８ｆ−タグ付加インヒビターおよび前立腺癌についての画像化剤としてのその使用
CA3064277A1 (en) Cd206+ macrophage-specific molecular imaging probe compositions and methods and the noninvasive quantification of arterial wall macrophage infiltration in humans
BRPI0809442A2 (pt) Composições para terapia e formação de imagens direcionada
US20220211884A1 (en) Rk polypeptide radiopharmaceutical targeting her2 and preparation method thereof
JP2016528299A (ja) ビタミンｂ１２および内因子を含む組成物およびその使用方法
JP2022548749A (ja) 画像化及び治療用組成物
CN109789227A (zh) 用于癌症成像和疗法的放射性磷脂金属螯合物
US20170209584A1 (en) Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
US20170202969A1 (en) Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
EP3011976A1 (en) 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents
KR102389014B1 (ko) 신규 암 치료 및 진단용 방사성 화합물이 결합된 인간 EphA2 특이적 모노바디 제조법 및 그의 용도
US20130302243A1 (en) Radiolabeled nanosystem, process for the preparation thereof and its use
WO2025240771A1 (en) Small zwitterionic multimeric targeted drugs and methods of use and manufacture thereof
HK40062845A (zh) Psma-結合劑及其用途
CN119101005A (zh) 前列腺特异性膜抗原（psma）配体及其用途
Vassilikos COST TD1004 Action
HK1161248B (en) Psma-binding agents and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220617